Detalles de la búsqueda
1.
Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Br J Haematol
; 191(3): 426-432, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32779190
2.
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
Br J Haematol
; 183(2): 212-224, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30125946
3.
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Cancer Immunol Immunother
; 66(1): 91-102, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815572
4.
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
Haematologica
; 107(4): 1000-1003, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35045694
5.
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Haematologica
; 101(12): 1573-1580, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27198718
6.
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Haematologica
; 104(5): e208-e210, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30514799
7.
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Br J Haematol
; 182(4): 590-594, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28677818
8.
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
Leuk Res
; 122: 106945, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36115087
9.
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.
Haematologica
; 96(8): 1161-9, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21546498
10.
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.
EJHaem
; 2(3): 525-529, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35844699
11.
Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies.
J Immunol Methods
; 476: 112675, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31629742
12.
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Br J Haematol
; 144(1): 78-85, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19016731
13.
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Br J Haematol
; 159(5): 608-12, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23043283
14.
Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia.
Cytometry B Clin Cytom
; 72(6): 450-7, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17565749
15.
Strategies in the management of alemtuzumab-related side effects.
Semin Oncol
; 33(2 Suppl 5): S29-35, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16720201
16.
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.
Leuk Lymphoma
; 47(7): 1229-38, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16923551
17.
Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.
Med Oncol
; 23(1): 137-9, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16645240
18.
Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia.
Semin Hematol
; 41(3): 234-45, 2004 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15269883
19.
Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.
Hematol J
; 4(4): 248-52, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12872149
20.
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Med Oncol
; 19(4): 277-80, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-12512923